Novartis AG ADR (NVS)vsTela Bio Inc (TELA)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
TELA
Tela Bio Inc
$0.87
+1.72%
HEALTHCARE · Cap: $34.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 70380% more annual revenue ($56.58B vs $80.28M). NVS leads profitability with a 23.9% profit margin vs -48.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
TELA
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+89.8%
Fair Value
$7.70
Current Price
$0.87
$6.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
18.2% revenue growth
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -223.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TELA
The strongest argument for TELA centers on Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : TELA
The primary concerns for TELA are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 26.98 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a declining stock while TELA is a growth play — different risk/reward profiles.
TELA carries more volatility with a beta of 0.99 — expect wider price swings.
TELA is growing revenue faster at 18.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 33/100), backed by strong 23.9% margins. TELA offers better value entry with a 89.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Tela Bio Inc
HEALTHCARE · MEDICAL DEVICES · USA
TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?